We are monitoring the impact of COVID-19 on North America Melanoma Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 793
Share on
Share on

North America Melanoma Therapeutics Market Research Report - Segmented By Cancer Stage, Cancer Type, Diagnosis, Treatment & Country (United States, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 793
Pages: 145

North America Melanoma Therapeutics Market Size (2021 to 2026)

The melanoma therapeutics market in North America was worth USD 1.22 billion in 2021 and is estimated to be growing at a CAGR of 15.95%, to reach USD 2.55 billion by 2026. 

The melanoma market has seen an unparalleled boost in market size, owing to a vigorously developing nature of melanoma treatments over the recent past.

Melanoma denotes the type of skin cancer that forms from the pigment-consisting cells in the skin. The elevated demand for innovative early-stage and advanced melanoma treatments, along with a thriving patient base, has generated an imminent need for improved therapies in the melanoma market. Even though many treatment choices are accessible today, various immunotherapies and combination therapies are anticipated to arrive on the market.

The market for melanoma therapeutics in North America is primarily driven by factors such as an increase in melanoma cases, a high acceptance rate of therapeutics among the patients, and government efforts to promote improved melanoma care. Also, with the growing patient base and strong demand for novel early-stage and advanced melanoma medicines, the melanoma industry is in desperate need of better treatments. As a result, several immunotherapies and combination therapies are projected to enter the market, even though there are various therapeutic choices accessible. Because of their higher survival benefits and few side effects, these innovative medicines are predicted to be widely adopted. In addition, an untapped patient pool will contribute to a significant uptake of innovative drugs in the forecast period.

On the other hand, the increased account of research and development operations from private and public organizations for creating affordable and effective treatments is expected to improve the melanoma therapeutics market’s growth opportunities. In addition, the patent expiration of prominent medications is expected to provide numerous chances for the North American melanoma therapeutics market to grow over the forecast period.

The North American melanoma therapeutics market’s growth rate is predicted to be hampered by the issues such as a lack of awareness in some emerging nations and the high cost of treatment. Furthermore, the melanoma therapeutics market is being held back by the economic downturn and regulatory problems.

This research report on the North America Melanoma Therapeutics Market is segmented and sub-segmented into the following categories:

By Cancer Stage:

  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

By Cancer Type:

  • Nodular Melanoma
  • Acral Lentiginous Melanoma
  • Superficial Spreading Melanoma
  • Lentigno Maligna Melanoma
  • Amelanotic Melanoma
  • Others

By Diagnosis:

  • Ultrasound
  • Blood Tests
  • Dermatoscopy
  • Sentinel Lymph Node Biopsy
  • X-rays
  • CT Scan

By Treatment:

  • Early Melanoma
  • Advanced Melanoma-Biological Therapy
  • Targeted Therapy
  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Immune Therapy

By Country: 

  • United States
  • Canada
  • Rest of North America

Geographically, the North American regional market held the largest share of the global Melanoma therapeutics market in 2020. The market is projected to witness a prominent share during the forecast period. The factors such as the rising number of melanoma patients and technical improvements in this region are driving the market growth. Furthermore, the increasing incidence of melanoma and other skin malignancies is considerably propelling this region’s market expansion. Melanoma infected roughly 88,000 persons in the United States in 2017, according to the CDC. As a result, this measurement will aid in the management of melanoma cases in the coming years.

Furthermore, the United States largely contributes due to favorable payment rules for treating diseases and the government’s development of unmet patient requirements. The Surgeon General Call to Action to Prevent Skin Cancer was announced in July 2014 by the Office of the Surgeon General, making skin cancer prevention a top priority for the country. The Call of Action outlined effective skin cancer prevention techniques and urged all community sectors to confront skin cancer as a significant public health issue. Since the Call of Action was issued, a growing community of national, state and local partners has worked hard to help prevent skin cancer in the United States.

The U.S. melanoma therapeutics market dominated the North American market with a significant share in 2020, and it is likely to continue its growth throughout the forecast period. In the United States, over 98% of melanoma are localized. In the United States, skin cancer is the most frequent cancer. Biologic therapy, immune therapy, radiation therapy, chemotherapy, and surgery are all options for melanoma treatment. California has the largest melanoma treatment market in the United States, followed by Florida. Further, the market is expected to be driven by technological advancements in melanoma therapy and diagnostics in the United States.

KEY MARKET PLAYERS:

Companies playing a dominant role in the North America melanoma therapeutics market profiled in this report are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By cancer stage                      

                             5.1.1 Stage 0     

                             5.1.2 Stage I      

                             5.1.3 Stage II     

                             5.1.4 Stage III   

                             5.1.5 Stage IV   

              5.2 By cancer type                        

                             5.2.1 Nodular melanoma           

                             5.2.2 Acral lentiginous melanoma          

                             5.2.3 Superficial spreading melanoma  

                             5.2.4 Lentigno maligna melanoma         

                             5.2.5 Amelanotic melanoma     

                             5.2.6 Others     

              5.3 By Diagnosis                           

                             5.3.1 Ultrasound            

                             5.3.2 Blood Tests           

                             5.3.3 Dermatoscopy      

                             5.3.4 Sentinel lymph node biopsy           

                             5.3.5 X-rays       

                             5.3.6 CT Scan    

              5.4 By Treatment                         

                             5.4.1 Early melanoma   

                             5.4.2 Advanced melanoma        

                                           5.4.2.1 Biological therapy

                                           5.4.2.2 Targeted therapy

                                           5.4.2.3 Surgery

                                           5.4.2.4 Chemotherapy

                                           5.4.2.5 Radiotherapy

                                           5.4.2.6 Immune therapy

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 United States                          

              6.3 Canada                      

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Bristol-Myers Squibb Co                     

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Merck and Co                         

              9.3 F. Hoffmann-La Roche                        

              9.4 Amgen Inc                

              9.5 Celgene Corp                          

              9.6 Daiichi Sankyo                        

              9.7 Pfizer Inc                   

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures  

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Melanoma Therapeutics Market By Region, From 2021 to 2026 (USD Billion)
  2. North America Melanoma Therapeutics Market By Cancer stage , From 2021 to 2026 (USD Billion)
  3. North America Stage 0 Market By Region, From 2021 to 2026 (USD Billion)
  4. North America Stage I Market By Region, From 2021 to 2026 (USD Billion)
  5. North America Stage II Market By Region, From 2021 to 2026 (USD Billion)
  6. North America Stage III Market By Region, From 2021 to 2026 (USD Billion)
  7. North America Stage IV Market By Region, From 2021 to 2026 (USD Billion)
  8. North America Melanoma Therapeutics Market By Cancer type , From 2021 to 2026 (USD Billion)
  9. North America Nodular melanoma Market By Region, From 2021 to 2026 (USD Billion)
  10. North America Acral lentiginous melanoma Market By Region, From 2021 to 2026 (USD Billion)
  11. North America Superficial spreading melanoma Market By Region, From 2021 to 2026 (USD Billion)
  12. North America Lentigno maligna melanoma Market By Region, From 2021 to 2026 (USD Billion)
  13. North America Amelanotic melanoma Market By Region, From 2021 to 2026 (USD Billion)
  14. North America Other cancers Market By Region, From 2021 to 2026 (USD Billion)
  15. North America Melanoma Therapeutics Market By Diagnosis, From 2021 to 2026 (USD Billion)
  16. North America Ultrasound Market By Region, From 2021 to 2026 (USD Billion)
  17. North America Blood Tests Market By Region, From 2021 to 2026 (USD Billion)
  18. North America Dermatoscopy Market By Region, From 2021 to 2026 (USD Billion)
  19. North America Sentinel lymph node biopsy Market By Region, From 2021 to 2026 (USD Billion)
  20. North America X-rays Market By Region, From 2021 to 2026 (USD Billion)
  21. North America CT Scan Market By Region, From 2021 to 2026 (USD Billion)
  22. North America Melanoma Therapeutics Market By Treatment, From 2021 to 2026 (USD Billion)
  23. North America early melanoma Market By Region, From 2021 to 2026 (USD Billion)
  24. North America advanced melanoma Market By Region, From 2021 to 2026 (USD Billion)
  25. North America Melanoma Therapeutics Market By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  26. North America Biological therapy Market By Region, From 2021 to 2026 (USD Billion)
  27. North America Targeted therapy Market By Region, From 2021 to 2026 (USD Billion)
  28. North America Surgery Market By Region, From 2021 to 2026 (USD Billion)
  29. North America Chemotherapy Market By Region, From 2021 to 2026 (USD Billion)
  30. North America Radiotherapy Market By Region, From 2021 to 2026 (USD Billion)
  31. North America Immune therapy Market By Region, From 2021 to 2026 (USD Billion)
  32. United States Melanoma Therapeutics Market By Cancer stage , From 2021 to 2026 (USD Billion)
  33. United States Melanoma Therapeutics Market By Cancer type , From 2021 to 2026 (USD Billion)
  34. United States Melanoma Therapeutics Market By Diagnosis, From 2021 to 2026 (USD Billion)
  35. United States Melanoma Therapeutics Market By Treatment, From 2021 to 2026 (USD Billion)
  36. United States Melanoma Therapeutics Market By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  37. Canada Melanoma Therapeutics Market By Cancer stage , From 2021 to 2026 (USD Billion)
  38. Canada Melanoma Therapeutics Market By Cancer type , From 2021 to 2026 (USD Billion)
  39. Canada Melanoma Therapeutics Market By Diagnosis, From 2021 to 2026 (USD Billion)
  40. Canada Melanoma Therapeutics Market By Treatment, From 2021 to 2026 (USD Billion)
  41. Canada Melanoma Therapeutics Market By Advanced Melanoma, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample